|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Acceleron Pharma Inc., of Cambridge, Mass., said preclinical results demonstrated that ACE-011, its anabolic bone agent to treat bone loss, preserved bone mass and architecture in a murine model of multiple myeloma. In the study, mice treated with ACE-011 maintained their bone mass, while untreated mice developed substantial bone loss as a result of the myeloma. Histomorphometry analysis revealed that mice given ACE-011 had normal bone formation parameters, while untreated mice had reduced bone formation and increased bone resorption. Data were presented at the International Myeloma Workshop in Kos, Greece.
o Amgen Inc., of Thousand Oaks, Calif., submitted ...
Related newspaper, magazine, and journal articles:
|
|
Article: Codon Devices Successfully Completes Significant ...
PR Newswire;
April 19, 2006 ;
700+ words
... ... Mass., April 19 /PRNewswire/ -- Codon Devices, the leader in the emerging field ... technology to complete the MGC's library. Codon Devices delivered all 21 assigned protein ... Chief Scientific Officer and Founder of Codon Devices, who presented the results to the ...
|
|